Intract Pharma, an oral drug delivery spinout company from UCL School of Pharmacy and Finch Therapeutics, Inc., a microbiome therapeutics company based in Somerville, MA, announced that Finch will use Intract’s Phloral® technology to develop a capsule for the targeted delivery of microbial communities into the colon.